Svante and Tenaska Forge Collaboration to Deliver Fully Integrated Carbon Capture and Storage Solutions
16.1.2025 16:03:00 EET | Business Wire | Press release
Svante Technologies Inc. (Svante), a leading innovator in carbon capture and removal technology, and Tenaska, a prominent CO2 transportation and sequestration service provider, have signed a Memorandum of Understanding (MOU) to collaborate on delivering cost-effective, integrated solutions for industrial carbon capture and storage (CCS). This collaboration represents a significant step toward addressing global industrial emissions and advancing the decarbonization of many industrial sectors, including pulp & paper, cement, steel, oil & gas, and more.
Under the terms of the non-exclusive MOU, Svante and Tenaska will combine their technology and services to provide end-to-end CCS value chain solutions to select customers. Svante’s cutting-edge solid sorbent-based carbon capture technology will facilitate efficient, environmentally responsible CO2 capture, while Tenaska will provide regional planning and infrastructure for CO2 transportation and storage. Tenaska is advancing a platform of mid- and early-stage projects in strategic locations across the United States, with Class VI permit applications filed for nearly 20 injection wells across multiple states.
Together, the companies aim to simplify the path to decarbonization for industrial emitters worldwide.
Key Objectives of the Collaboration:
- Integrated Carbon Management Solutions:
- Svante will focus on capturing CO2 emissions at industrial facilities, including related processes such as CO2 compression, conditioning, and liquefaction.
- Tenaska will manage CO2 transportation and sequestration, ensuring safe, secure, permanent storage deep underground.
- North America-wide Outreach and Customer Engagement:
- The joint initiative will actively promote carbon capture and storage to industrial emitters across North America, offering tailored solutions to meet diverse needs.
- Innovative Project Development:
- The collaboration will identify and assess commercially viable opportunities for CCS, leveraging the combined technical and operational expertise of both organizations.
Leadership Quotes:
“This collaboration is well aligned with Svante’s mission to make carbon capture accessible for industries worldwide,” said Matt Stevenson, Chief Revenue Officer of Svante. “By combining our technology with Tenaska’s extensive experience in CO2 transportation and storage, we can offer end-to-end solutions that accelerate the transition to a net-zero future.”
“Recognizing the synergies with our CCS development platform, Tenaska is proud to work with Svante to advance innovative solutions for carbon management,” said Bret Estep, Vice President, Tenaska Development. “Together, we aim to provide industrial customers with the tools and confidence to achieve their decarbonization goals.”
A Vision for the Future
The Svante-Tenaska collaboration underscores a shared commitment to providing business solutions that help industrial sectors reduce carbon emissions. By offering integrated, efficient, and scalable CCS solutions, the companies aim to unlock new opportunities for industries to meet their sustainability targets while maintaining operational excellence.
About Svante
Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.
About Tenaska
Consistently ranked among Forbes’ List of America’s Largest Private Companies, Tenaska is a leading energy company with business operations that span the energy value chain. Tenaska Marketing Ventures (TMV) and Tenaska Power Services Co. (TPS) are among the largest natural gas and electric power marketing companies in North America. The company has an operating fleet of 7,460 megawatts (MW) of natural gas and renewable generating facilities and throughout its history has developed, managed and/or operated approximately 22,000 MW of natural gas-fueled and renewable generation. Tenaska is actively developing 10 carbon sequestration projects capable of storing more than 50 million metric tons of CO2 per year, multiple natural gas-fueled generation projects and a development services portfolio of more than 35,000 MW of solar, wind, energy storage and green hydrogen projects. Tenaska seeks investment opportunities to allocate its capital into generation assets nationwide. For more information, visit www.tenaska.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116961790/en/
Contacts
Media Contacts:
Svante:
Colleen Nitta
Director of Marketing and Communications
604-970-2813
cnitta@svanteinc.com
Tenaska:
Timberly Ross
Senior Director, Community Relations
402-691-9517
tross@tenaska.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom